|
October 24, 2002
Dynavax Technologies Corporation
Files Registration Statement
For Initial Public Offering
BERKELEY, Calif., Oct. 24 /PRNewswire/
-- Dynavax Technologies Corporation
announced today that it has filed
a registration statement with the
Securities and Exchange Commission
for the initial public offering of
its common stock. All of the shares
are to be sold by the Company. The
underwriters for the
offering are Bear, Stearns & Co.
Inc., Deutsche Bank Securities, and
U.S. Bancorp Piper Jaffray Inc. The
offering will be made only by means
of a
prospectus. When available, copies
of the preliminary prospectus relating
to
this offering may be obtained from
Bear, Stearns & Co. Inc. at 383
Madison
Avenue, New York, New York 10179,
212-272-2000.
A registration statement relating
to these securities has been filed
with
the Securities and Exchange Commission
but has not yet become effective.
These securities may not be sold nor
may offers to buy be accepted prior
to
the time that the registration statement
becomes effective. This news release
shall not constitute an offer to sell
or the solicitation of an offer to
buy,
nor shall there be any sale of these
securities in any state or jurisdiction
in which such offer, solicitation,
or sale would be unlawful prior to
registration or qualification under
the securities laws of any such state
or
jurisdiction.
About
Dynavax Technologies
Dynavax Technologies is a privately
held biopharmaceutical company developing
innovative products to treat allergy,
inflammation-mediated diseases, infectious
diseases and cancer. The company’s
lead products are based on ImmunoStimulatory
Sequences (ISS), short DNA sequences
that enhance the ability of the immune
system to fight disease and prevent
inflammation. The company’s two
most advanced products are AIC, which
has provided positive results in recently
completed phase II clinical trials
for the treatment of ragweed allergy,
and a next-generation hepatitis B
vaccine that may offer single-dose
protection. Dynavax is also developing
an oral TNF-alpha synthesis inhibitor
initially for the treatment of rheumatoid
arthritis. The company has collaborations
with Aventis-Pasteur, Triangle Pharmaceuticals
and Stallergenes.
Contact:
Andrew Gengos
Chief Financial Officer
Dynavax Technologies Corporation
(510) 848-5100
|
